Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Futibatinib - Taiho Oncology/Taiho Pharmaceutical

Next Previous
Drug Profile

Futibatinib - Taiho Oncology/Taiho Pharmaceutical

Alternative Names: LYTGOBI; Lytgobi; TAS 120

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Taiho Oncology; Taiho Pharmaceutical
  • Class Amines; Antineoplastics; Ketones; Phenyl ethers; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Cholangiocarcinoma
  • Phase II/III Cancer
  • Phase II Breast cancer; Gastric cancer; Lymphoid leukaemia; Myeloid leukaemia; Oesophageal cancer; Solid tumours; Urogenital cancer
  • Phase I/II Non-small cell lung cancer
  • Preclinical Rhabdomyosarcoma

Most Recent Events

  • 24 Jun 2026 Phase-III clinical trials in Biliary cancer (Combination therapy, First-line therapy, Late-stage disease, Inoperable/Unresectable) in Thailand, South Korea, Japan, Australia (PO) (NCT07710885) (jRCT2071260018)
  • 03 Dec 2025 Launched for Cholangiocarcinoma (Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom (PO)
  • 29 Sep 2025 Taiho Oncology terminates the Phase-II clinical trials in Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in France and Spain (PO) due to strategic considerations (NCT04601857)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top